Rhythm Pharmaceuticals Q2 revenue rises to $71.3 million; RM-718 preliminary data released
Rhythm Pharmaceuticals reported second quarter 2026 net product revenue of $71.3 million from IMCIVREE, up from $48.5 million a year earlier, and a net loss attributable to common stockholders of $50.4 million, or $(0.73) per share, compared with $(0.75) per share a year earlier. The company also released preliminary Phase 2 data showing an 11.6% mean BMI reduction at 16 weeks for RM-718 in a small group of patients with acquired hypothalamic obesity, which shareholders may watch as the program advances.
Key points
- Q2 2026 net product revenue was $71.3 million, versus $48.5 million in Q2 2025; U.S. revenue was $51.0 million.
- Q2 2026 net loss attributable to common stockholders was $50.4 million, or $(0.73) per share, versus $48.0 million, or $(0.75) per share, in Q2 2025.
- RM-718 showed a mean BMI reduction of 11.6% from baseline at 16 weeks (n=7) in the ongoing Phase 2 trial, which enrolled eleven patients with acquired HO.
- Cash, cash equivalents and short-term investments were $330.9 million as of June 30, 2026, and the company expects these to fund planned operations for at least 24 months.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.